Daniel R. Chard - 13 Mar 2026 Form 4 Insider Report for MEDIFAST INC (MED)

Reporting relationship: Chairman & CEO, Director
Issuer ticker: MED
Reported as of: 13 Mar 2026
Net transaction value: +$178,725
SEC form: 4
Accepted by SEC: 27 Mar 2026, 17:51:17 UTC
Prior SEC filing: 17 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Jason L. Groves, attorney-in-fact

Key filing fact

Daniel R. Chard filed Form 4 for MEDIFAST INC (MED) on 27 Mar 2026.

Key facts

This page summarizes Daniel R. Chard's Form 4 filing for MEDIFAST INC (MED).
6 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 27 Mar 2026, 17:51.

Change

Previous filing in this sequence was filed on 17 Jun 2025.
Current net transaction value: +$178,725.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001289557 Primary reporting owner

Chard Daniel R

Relationship: Chairman & CEO, Director
Address: C/O MEDIFAST, INC., 1501 S. CLINTON STREET, SUITE 500, BALTIMORE
Signature: /s/ Jason L. Groves, attorney-in-fact
Signature date: 27 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MED transaction

Common Stock

Tax liability

Transaction value
Shares: -7,075
Change %: -4%
Price: $9.62^*
Shares after: 169,171
Date: 13 Mar 2026
Ownership: Direct
Footnotes: F1

MED transaction

Common Stock

Tax liability

Transaction value
Shares: -2,638
Change %: -1.6%
Price: $10.05^*
Shares after: 166,533
Date: 17 Mar 2026
Ownership: Direct
Footnotes: F1

MED transaction

Common Stock

Purchase

Transaction value: $178,725
Shares: +17,678
Change %
Price: $10.11
Shares after: 17,678
Date: 20 Mar 2026
Ownership: Dan and Allyson as Joint Tenants
Footnotes: F2, F3

MED transaction

Common Stock

Tax liability

Transaction value
Shares: -20,095
Change %: -12%
Price: $9.59^*
Shares after: 146,438
Date: 25 Mar 2026
Ownership: Direct
Footnotes: F1

MED transaction

Common Stock

Award

Transaction value
Shares: +36,968
Change %: +25%
Price: $0.000000^*
Shares after: 183,406
Date: 25 Mar 2026
Ownership: Direct
Footnotes: F5

MED transaction

Common Stock

Award

Transaction value
Shares: +4,827
Change %: +2.6%
Price: $0.000000^*
Shares after: 188,233
Date: 25 Mar 2026
Ownership: Direct
Footnotes: F6

MED holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 149,698
Date: 13 Mar 2026
Ownership: The Dan and Allyson Family Irrevocable Trust
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents the number of shares withheld by the Issuer upon the vesting of a restricted stock unit grant to cover the executive's withholding tax associated with the satisfaction of all vesting conditions. The number of shares withheld is based upon the closing price of a share of Medifast common stock on the vesting date, or if the vesting date fell on a weekend or market holiday, upon the closing price of a share of Medifast common stock on the most recent prior market day.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $10.04 to $10.18, inclusive.

Footnote F3

These shares are directly owned by a joint account of which the reporting person owns as a joint tenant with his spouse.

Footnote F4

These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee.

Footnote F5

Represents a grant of restricted stock units issued to the reporting person under the 2012 Share Incentive Plan that will vest in three equal annual installments beginning on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Footnote F6

Represents shares of common stock issued upon the vesting and settlement of performance stock units previously granted to the reporting person on March 17, 2023, which were earned based on achievement of performance criteria certified by the Compensation Committee on February 5, 2026. Each PSU represented a contingent right to receive one share of common stock.